Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Plasma cell leukaemia
Focus Therapeutic Use
Acronyms EMN12HO129

04 Sep 2023 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.
13 Dec 2022 Status changed from recruiting to completed, based on results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
13 Dec 2022 Results (At the data cut-off July 1, 2022), for patients in the age-group greater than or equal to 66 years, presented at the 64th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com